Authors: Maliepaard, M van Gastelen, MA Tohgo, A Hausheer, FH van Waardenburg, RCAM de Jong, LA Pluim, D Beijnen, JH Schellens, JHM

Citation: M. Maliepaard et al., Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918, CLIN CANC R, 7(4), 2001, pp. 935-941

Authors: Arimori, K Kuroki, N Kumamoto, A Tanoue, N Nakano, M Kumazawa, E Tohgo, A Kikuchi, M

Citation: K. Arimori et al., Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents, PHARM RES, 18(6), 2001, pp. 814-822

Authors: Pierce, KL Tohgo, A Ahn, S Field, ME Luttrell, LM Lefkowitz, RJ

Citation: Kl. Pierce et al., Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors - A co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding, J BIOL CHEM, 276(25), 2001, pp. 23155-23160

Authors: Okamoto, H Takasawa, S Nata, K Kato, I Tohgo, A Noguchi, N

Citation: H. Okamoto et al., Physiological and pathological significance of the CD38-cyclic ADP-ribose signaling system, CHEM IMMUNO, 75, 2000, pp. 121-145

Authors: Ishii, M Iwahana, M Mitsui, I Minami, M Imagawa, S Tohgo, A Ejima, A

Citation: M. Ishii et al., Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6, ANTI-CANC D, 11(5), 2000, pp. 353-362

Authors: Lawrence, RA Izbicka, E De Jager, RL Tohgo, A Clark, GM Weitman, SD Rowinsky, EK Von Hoff, DD

Citation: Ra. Lawrence et al., Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells, ANTI-CANC D, 10(7), 1999, pp. 655-661